At the news
? BULLISHIMPACT 6/10 8-K filed Nov 3, 2026 at 08:22 ET
Compass Pathways reported Q3 2026 results with a GAAP net loss of $9.8M ($0.07 basic / $0.31 diluted per share), compared to a $137.7M loss in Q3 2025. The improved bottom line was driven by a $40.8M non-cash gain on warrant liabilities. The key catalyst is the imminent completion of the NDA submission for COMP360 in TRD, expected within two weeks, with potential for accelerated FDA review and commercial launch in H1 2027. Cash stood at $444M, sufficient into 2028.
- Final NDA submission for COMP360 in TRD will be filed in the next two weeks, with rolling review underway.
- National Priority Voucher could shorten FDA review to 1-2 months; White House Executive Order supports rapid DEA rescheduling.
- Commercial launch on track for H1 2027, subject to FDA approval.
- Cash and cash equivalents of $444M as of September 30, 2026, sufficient into 2028.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access